A Bioequivalence Study of Ezetimibe/Rosuvastatin Fixed Dose Combination (10 mg/10 mg) Versus the Individual Formulations Taken Concomitantly

[1] Nelson RH(2013)Hyperlipidemia as a risk factor for cardiovascular disease Prim Care 40 195-211

[2] Lin C-F(2018)Epidemiology of dyslipidemia in the Asia Pacific region Int J Gerontol 12 2-6

[3] Chang Y-H(2016)Estimating the future burden of cardiovascular disease and the value of lipid and blood pressure control therapies in China BMC Health Serv Res 16 175-2330

[4] Chien S-C(2020)Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel Eur Heart J 41 2313-e1143

[5] Lin Y-H(2019)2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines Circulation 139 e1082-278

[6] Yeh H-Y(2008)Combination therapy in cholesterol reduction: focus on ezetimibe and statins Vasc Health Risk Manag 4 267-1155

[7] Stevens W(2012)Lowering plasma cholesterol by raising LDL receptors—revisited N Engl J Med 366 1154-427

[8] Peneva D(2012)Ezetimibe therapy: mechanism of action and clinical update Vasc Health Risk Manag 8 415-117

[9] Li JZ(2017)Combination therapy of rosuvastatin and ezetimibe in patients with high cardiovascular risk Clin Ther 39 107-300

[10] Borén J(2013)Combine and conquer: advantages and disadvantages of fixed-dose combination therapy Diabetes Obes Metab 15 291-241.e4

[1] Nelson RH(2013)Hyperlipidemia as a risk factor for cardiovascular disease Prim Care 40 195-211

[2] Lin C-F(2018)Epidemiology of dyslipidemia in the Asia Pacific region Int J Gerontol 12 2-6

[3] Chang Y-H(2016)Estimating the future burden of cardiovascular disease and the value of lipid and blood pressure control therapies in China BMC Health Serv Res 16 175-2330

[4] Chien S-C(2020)Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel Eur Heart J 41 2313-e1143

[5] Lin Y-H(2019)2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines Circulation 139 e1082-278

[6] Yeh H-Y(2008)Combination therapy in cholesterol reduction: focus on ezetimibe and statins Vasc Health Risk Manag 4 267-1155

[7] Stevens W(2012)Lowering plasma cholesterol by raising LDL receptors—revisited N Engl J Med 366 1154-427

[8] Peneva D(2012)Ezetimibe therapy: mechanism of action and clinical update Vasc Health Risk Manag 8 415-117

[9] Li JZ(2017)Combination therapy of rosuvastatin and ezetimibe in patients with high cardiovascular risk Clin Ther 39 107-300

[10] Borén J(2013)Combine and conquer: advantages and disadvantages of fixed-dose combination therapy Diabetes Obes Metab 15 291-241.e4